Information on this site is for research purposes only.

Close Icon

Tag Archives: BRCA1

Post Image

Tempol is synthetically lethal with a BRCA1-deficiency in breast cancer cells

Cell Cycle. 2012 Dec 1;11(23):4402-13. BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies. Martinez-Outschoorn UE1, Balliet R, Lin Z, Whitaker-Menezes D, Birbe RC, Bombonati A, Pavlides S, Lamb R, Sneddon S, Howell A, Sotgia F, Lisanti MP. 1Jefferson Stem Cell Biology and Regenerative Medicine […]

Take a Tour 
Post Image

Tempol disrupts CtBP1 binding to Brca1

Oncogene. 2010 Dec 16;29(50):6603-8. Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1 Deng Y1, Liu J, Han G, Lu SL, Wang SY, Malkoski S, Tan AC, Deng C, Wang XJ, Zhang Q. 1Department of Dermatology, University of Colorado, Denver, Aurora, CO 80045, USA. Abstract C-terminal binding protein 1 (CtBP1) is a transcriptional co-repressor and metabolic […]

Take a Tour 
Post Image

TEMPOL for Cancer

TEMPOL for Cancer– Why Treat Fibrocystic Change? Jan 11, 2015 Peter H Proctor, PhD, MD TEMPOL is a small-molecule “SOD-mimetic”, effective in a variety of experimental cancer models, both in vivo and in vitro. Tracing back to the Warburg effect, its putative mechanism of action is destruction of reactive oxygen species (ROS). These drive the […]

Take a Tour 
Post Image

TEMPOL-H for Fibrocystic Breast Disease– Case Report.

SFRBM (Society For Free Radical Biology and Medicine) Meeting, Nov. 20-24, 2013, San Antonio, TX Peter Proctor, Donna RollingProctor ABSTRACT Variably presenting with painful cysts and mastodynia, fibrocystic disease of breast (FD) affects 30-40% of women. FD complicates breast cancer diagnosis by requiring work-up of lumps to rule-out malignancy and by obscuring malignant lesions. Although […]

Take a Tour 
Visit Us On TwitterVisit Us On FacebookVisit Us On Google PlusVisit Us On YoutubeCheck Our Feed